To the Editor:
The authors want to clarify the definition of "biosimilar" based on "Regulatory expectations and risk assessment for biotherapeutic products. World Health Organization 2014. available from http://www.who.int/biologicals/WHO_Risk_Assessment_for_Biotherapeutics_1st_PC_24_Jan_2014.pdf"
In this article (J Korean Med Sci 2015;30:378-384), as Abcertin® does not meet the exact definition of biosimilar, the authors would like to delete the phrases "a biosimilar of imiglucerase" in Page 379 and "a new biosimilar to imiglucerase" in Page 382.
Thank you.
Sincerely yours,
Yoo HW